文献速递临床试验与 GCP流行病学与生物统计

质子泵抑制剂与组胺-2受体拮抗剂预防应激性溃疡对ICU机械通气患者院内死亡率的影响:PEPTIC随机临床试验

Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

PEPTIC集群交叉随机试验在5国50个ICU比较质子泵抑制剂(PPI)与组胺-2受体拮抗剂(H2RB)预防应激性溃疡对机械通气患者90天院内死亡率的影响。结果显示PPI组死亡18.3%、H2RB组17.5%,差异未达显著性(RR 1.05,95%CI 1.00-1.10;

要点

  • PPI与H2RB预防应激性溃疡的90天院内死亡率无显著差异。
  • PPI组临床重要上消化道出血发生率低于H2RB组。
  • 两组艰难梭菌感染及ICU/住院时长无显著差异。

核心结论

  • 在接受有创机械通气的ICU患者中,PPI与H2RB预防应激性溃疡的院内死亡率分别为18.3%与17.5%,差异未达显著性阈值。

研究设计与样本

  • 集群交叉随机临床试验,2016年8月至2019年1月在5国50个ICU进行,每个ICU按随机顺序先后使用PPI优先或H2RB优先策略各6个月。
  • ICU入科24小时内需有创机械通气的患者纳入,随访至住院90天。

主要发现

  • 艰难梭菌感染率及ICU和住院时长在两组间无显著差异。
  • PPI组1例患者报告1起不良事件(过敏反应)。
  • 按ICU随机分配至PPI的患者中估计4.1%实际接受H2RB,分配至H2RB的患者中估计20.1%实际接受PPI。

临床怎么用

  • 对于需要机械通气的ICU患者,选择PPI或H2RB预防应激性溃疡时,死亡率无显著差异,但PPI可能降低临床重要上消化道出血风险。
  • 临床决策需结合患者出血风险与药物相关不良事件,并考虑交叉用药对结果解读的影响。

局限性

  • 研究解读可能受限于实际用药与随机分配策略之间的交叉。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Proton pump inhibitors (PPIs) or histamine-2 receptor blockers (H2RBs) are often prescribed for patients as stress ulcer prophylaxis drugs in the intensive care unit (ICU). The comparative effect of these drugs on mortality is unknown. OBJECTIVE: To compare in-hospital mortality rates using PPIs vs H2RBs for stress ulcer prophylaxis. DESIGN, SETTING, AND PARTICIPANTS: Cluster crossover randomized clinical trial conducted at 50 ICUs in 5 countries between August 2016 and January 2019. Patients requiring invasive mechanical ventilation within 24 hours of ICU admission were followed up for 90 days at the hospital. INTERVENTIONS: Two stress ulcer prophylaxis strategies were compared (preferential use with PPIs vs preferential use with H2RBs). Each ICU used each strategy sequentially for 6 months in random order; 25 ICUs were randomized to the sequence with use of PPIs and then use of H2RBs and 25 ICUs were randomized to the sequence with use of H2RBs and then use of PPIs (13 436 patients randomized by site to PPIs and 13 392 randomized by site to H2RBs). MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality within 90 days during index hospitalization. Secondary outcomes were clinically important upper gastrointestinal bleeding, Clostridioides difficile infection, and ICU and hospital lengths of stay. RESULTS: Among 26 982 patients who were randomized, 154 opted out, and 26 828 were analyzed (mean [SD] age, 58 [17.0] years; 9691 [36.1%] were women). There were 26 771 patients (99.2%) included in the mortality analysis; 2459 of 13 415 patients (18.3%) in the PPI group died at the hospital by day 90 and 2333 of 13 356 patients (17.5%) in the H2RB group died at the hospital by day 90 (risk ratio, 1.05 [95% CI, 1.00 to 1.10]; absolute risk difference, 0.93 percentage points [95% CI, -0.01 to 1.88] percentage points; P = .054). An estimated 4.1% of patients randomized by ICU site to PPIs actually received H2RBs and an estimated 20.1% of patients randomized by ICU site to H2RBs actually received PPIs. Clinically important upper gastrointestinal bleeding occurred in 1.3% of the PPI group and 1.8% of the H2RB group (risk ratio, 0.73 [95% CI, 0.57 to 0.92]; absolute risk difference, -0.51 percentage points [95% CI, -0.90 to -0.12 percentage points]; P = .009). Rates of Clostridioides difficile infection and ICU and hospital lengths of stay were not significantly different by treatment group. One adverse event (an allergic reaction) was reported in 1 patient in the PPI group. CONCLUSIONS AND RELEVANCE: Among ICU patients requiring mechanical ventilation, a strategy of stress ulcer prophylaxis with use of proton pump inhibitors vs histamine-2 receptor blockers resulted in hospital mortality rates of 18.3% vs 17.5%, respectively, a difference that did not reach the significance threshold. However, study interpretation may be limited by crossover in the use of the assigned medication. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12616000481471.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Young PJ, Bagshaw SM, Forbes AB, et al. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial. JAMA. 2020. PMID: 31950977. doi:10.1001/jama.2019.22190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。